No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia

References

• Adler , L. E. , Hoffer , L. D. , Wiser , A. and Freedman , R. 1993 . Normalization of auditory physiology by cigarette smoking in schizophrenic patients . Am J Psychiatry , 150 ( 12 ) : 1856 – 1861 .
   PubMed Web of Science ®Google Scholar
• Andreasen , N. C. 1984a . The Scale for the Assessment of Negative Symptoms (SANS) , Iowa City, IA : University of Iowa .
   Google Scholar
• Andreasen , N. C. 1984b . The Scale for the Assessment of Positive Symptoms (SAPS) , Iowa City, IA : University of Iowa .
   Google Scholar
• Arango , C. , Buchanan , R. W. , Kirkpatrick , B. and Carpenter , W. T. 2004 . The deficit syndrome in schizophrenia: Implications for the treatment of negative symptoms . European Psychiatry , 19 ( 1 ) : 21 – 26 .
   PubMed Web of Science ®Google Scholar
• Bilder , R. M. , Lipschutz-Broch , L. , Reiter , G. , Geisler , S. , Mayerhoff , D. and Lieberman , J. A. 1991 . Neuropsychological deficits in the early course of first episode schizophrenia . Schizophrenia Research , 5 ( 3 ) : 198 – 199 .
   PubMed Web of Science ®Google Scholar
• Bowie , C. R. , Reichenberg , A. , Patterson , T. L. , Heaton , R. K. and Harvey , P. D. 2006 . Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms . American Journal of Psychiatry , 163 ( 3 ) : 418 – 425 .
   PubMed Web of Science ®Google Scholar
• Braff , D. L. and Saccuzzo , D. P. 1982 . Effect of antipsychotic medication on speed of information processing in schizophrenic patients . American Journal of Psychiatry , 139 ( 9 ) : 1127 – 1130 .
   PubMed Web of Science ®Google Scholar
• Buchanan , R. W. , Summerfelt , A. , Tek , C. and Gold , J. 2003 . An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia . Schizophrenia Research , 59 ( 1 ) : 29 – 33 .
   PubMed Web of Science ®Google Scholar
• Censits , D. M. , Ragland , J. D. , Gur , R. C. and Gur , R. E. 1997 . Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: A longitudinal study . Schizophrenia Research , 24 ( 3 ) : 289 – 298 .
   PubMed Web of Science ®Google Scholar
• Davis , K. L. , Kahn , R. S. , Ko , G. and Davidson , M. 1991 . Dopamine in schizophrenia: A review and reconceptualization . American Journal of Psychiatry , 148 ( 11 ) : 1474 – 1486 .
   PubMed Web of Science ®Google Scholar
• Edwards , J. , Pattison , P. E. , Jackson , H. J. and Wales , R. J. 2001 . Facial affect and affective prosody recognition in first-episode schizophrenia . Schizophrenia Research , 48 ( 2–3 ) : 235 – 253 .
   PubMed Web of Science ®Google Scholar
• Erickson , S. K. , Schwarzkopf , S. B. , Palumbo , D. , Badgley-Fleeman , J. , Smirnow , A. M. and Light , G. A. 2005 . Efficacy and tolerability of low-dose donepezil in schizophrenia . Clinical Neuropharmacologyl , 28 ( 4 ) : 179 – 184 .
   PubMed Web of Science ®Google Scholar
• Evins , A. E. , Fitzgerald , S. M. , Wine , L. , Rosselli , R. and Goff , D. C. 2000 . Placebo-controlled trial of glycine added to clozapine in schizophrenia . American Journal of Psychiatry , 157 ( 5 ) : 826 – 828 .
   PubMed Web of Science ®Google Scholar
• Ferreri , F. , Agbokou , C. and Gauthier , S. 2006 . Cognitive dysfunctions in schizophrenia: Potential benefits of cholinesterase inhibitor adjunctive therapy . Journal of Psychiatry & Neuroscience , 31 ( 6 ) : 369 – 376 .
   PubMed Web of Science ®Google Scholar
• Freudenreich , O. , Herz , L. , Deckersbach , T. , Evins , A. E. , Henderson , D. C. Cather , C. 2005 . Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial . Psychopharmacology (Berlin) , 181 ( 2 ) : 358 – 363 .
   PubMed Web of Science ®Google Scholar
• Friedman , J. I. , Adler , D. N. , Howanitz , E. , Harvey , P. D. , Brenner , G. Temporini , H. 2002 . A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia . Biological Psychiatry , 51 ( 5 ) : 349 – 357 .
   PubMed Web of Science ®Google Scholar
• Friedman , J. I. , Adler , D. N. , Temporini , H. D. , Kemether , E. , Harvey , P. D. White , L. 2001 . Guanfacine treatment of cognitive impairment in schizophrenia . Neuropsychopharmacology , 25 ( 3 ) : 402 – 409 .
   PubMed Web of Science ®Google Scholar
• Friedman , J. I. , Ocampo , R. , Elbaz , Z. , Parrella , M. , White , L. Bowler , S. 2005 . The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia . Journal of Clinical Psychopharmacology , 25 ( 3 ) : 237 – 242 .
   PubMed Web of Science ®Google Scholar
• Friedman , J. I. , Stewart , D. G. and Gorman , J. M. 2004 . Potential noradrenergic targets for cognitive enhancement in schizophrenia . CNS Spectrum , 9 ( 5 ) : 350 – 355 .
   PubMed Web of Science ®Google Scholar
• Furey , M. L. , Pietrini , P. , Alexander , G. E. , Schapiro , M. B. and Horwitz , B. 2000 . Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: A positron emission tomography regional cerebral blood flow study in healthy humans . Brain Research Bulletin , 51 ( 3 ) : 213 – 218 .
   PubMed Web of Science ®Google Scholar
• Gold , S. , Arndt , S. , Nopoulos , P. , O'Leary , D. S. and Andreasen , N. C. 1999 . Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia . American Journal of Psychiatry , 156 ( 9 ) : 1342 – 1348 .
   PubMed Web of Science ®Google Scholar
• Green , M. F. 1996 . What are the functional consequences of neurocognitive deficits in schizophrenia? . American Journal of Psychiatry , 153 ( 3 ) : 321 – 330 .
   PubMed Web of Science ®Google Scholar
• Gur , R. C. , Ragland , J. D. , Moberg , P. J. , Bilker , W. B. , Kohler , C. Siegel , S. J. 2001 . Computerized neurocognitive scanning: II. The profile of schizophrenia . Neuropsychopharmacology , 25 ( 5 ) : 777 – 788 .
   PubMed Web of Science ®Google Scholar
• Hamilton , M. 1960 . A rating scale for depression . Journal of Neurology, Neurosurgery, and Psychiatry , 23 : 56 – 62 .
   PubMed Web of Science ®Google Scholar
• Harvey , P. D. and Keefe , R. S. 2001 . Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment . American Journal of Psychiatry , 158 ( 2 ) : 176 – 184 .
   PubMed Web of Science ®Google Scholar
• Hasselmo , M. E. and Bower , J. M. 1993 . Acetylcholine and memory . Trends in Neuroscience , 16 ( 6 ) : 218 – 222 .
   PubMed Web of Science ®Google Scholar
• Heinrichs , D. W. , Hanlon , T. E. and Carpenter , W. T. Jr . 1984 . The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome . Schizophrenia Bulletin , 10 ( 3 ) : 388 – 398 .
   PubMed Web of Science ®Google Scholar
• Herbener , E. S. , Hill , S. K. , Marvin , R. W. and Sweeney , J. A. 2005 . Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia . American Journal of Psychiatry , 162 ( 9 ) : 1746 – 1748 .
   PubMed Web of Science ®Google Scholar
• Hoff , A. L. , Sakuma , M. , Wieneke , M. , Horon , R. , Kushner , M. and DeLisi , L. E. 1999 . Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia . American Journal of Psychiatry , 156 ( 9 ) : 1336 – 1341 .
   PubMed Web of Science ®Google Scholar
• Hogarty , G. E. , Flesher , S. , Ulrich , R. , Carter , M. , Greenwald , D. Pogue-Geile , M. 2004 . Cognitive enhancement therapy for schizophrenia: Effects of a 2-year randomized trial on cognition and behavior . Archives of General Psychiatry , 61 ( 9 ) : 866 – 876 .
   PubMed Web of Science ®Google Scholar
• Howard , A. K. , Thornton , A. E. , Altman , S. and Honer , W. G. 2002 . Donepezil for memory dysfunction in schizophrenia . Journal of Psychopharmacology , 16 ( 3 ) : 267 – 270 .
   PubMed Web of Science ®Google Scholar
• Keefe , R. S. , Silva , S. G. , Perkins , D. O. and Lieberman , J. A. 1999 . The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis . Schizophrenia Bulletin , 25 ( 2 ) : 201 – 222 .
   PubMed Web of Science ®Google Scholar
• Klein , C. and Andersen , B. 1991 . On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls . Journal of Psychophysiology , 5 : 361 – 369 .
   Google Scholar
• Kohler , C. G. , Bilker , W. , Hagendoorn , M. , Gur , R. E. and Gur , R. C. 2000 . Emotion recognition deficit in schizophrenia: Association with symptomatology and cognition . Biological Psychiatry , 48 ( 2 ) : 127 – 136 .
   PubMed Web of Science ®Google Scholar
• Kohler , C. G. , Turner , T. H. , Bilker , W. B. , Brensinger , C. M. , Siegel , S. J. Kanes , S. J. 2003 . Facial emotion recognition in schizophrenia: Intensity effects and error pattern . American Journal of Psychiatry , 160 ( 10 ) : 1768 – 1774 .
   PubMed Web of Science ®Google Scholar
• Kurtz , M. M. 2005 . Neurocognitive impairment across the lifespan in schizophrenia: An update . Schizophrenia Research , 74 ( 1 ) : 15 – 26 .
   PubMed Web of Science ®Google Scholar
• Kurtz , M. M. , Moberg , P. J. , Gur , R. C. and Gur , R. E. 2004 . Results from randomized, controlled trials of the effects of cognitive remediation on neurocognitive deficits in patients with schizophrenia . Psychological Medicine , 34 ( 3 ) : 569 – 570 .
   PubMedGoogle Scholar
• MacEwan , G. W. , Ehmann , T. S. , Khanbhai , I. and Wrixon , C. 2001 . Donepezil in schizophrenia—is it helpful? An experimental design case study . Acta Psychiatrica Scandinavica , 104 ( 6 ) : 469 – 472 .
   PubMed Web of Science ®Google Scholar
• Mazeh , D. , Zemishlani , H. , Barak , Y. , Mirecki , I. , & Paleacu , D. ( 2006 ). Donepezil for negative signs in elderly patients with schizophrenia: An add-on, double-blind, crossover, placebo-controlled study . International Psychogeriatrics , 18 (3) , 429 – 436 .
   PubMed Web of Science ®Google Scholar
• Millan , M. J. 2005 . N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: Novel insights and clinical perspectives . Psychopharmacology (Berlin) , 179 ( 1 ) : 30 – 53 .
   PubMed Web of Science ®Google Scholar
• Mitchell , E. S. and Neumaier , J. F. 2005 . 5-HT6 receptors: A novel target for cognitive enhancement . Pharmacological Therapies , 108 ( 3 ) : 320 – 333 .
   PubMed Web of Science ®Google Scholar
• Moller , H. J. 2003 . Management of the negative symptoms of schizophrenia: New treatment options . CNS Drugs , 17 ( 11 ) : 793 – 823 .
   PubMed Web of Science ®Google Scholar
• Noren , U. , Bjorner , A. , Sonesson , O. , & Eriksson , L. ( 2006 ). Galantamine added to antipsychotic treatment in chronic schizophrenia: Cognitive improvement? Schizophrenia Research , 85 (1–3) , 302 – 304 .
   PubMedGoogle Scholar
• Purdon , S. R. E. , Jones , B. D. , Stip , E. , Labelle , A. , Addington , D. David , S. 2001 . Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol . Archives in General Psychiatry , 57 : 249 – 258 .
   Google Scholar
• Risch , S. C. , Horner , M. D. , McGurk , S. R. , Palecko , S. , Markowitz , J. S. , Nahas , Z. , et al. ( 2005 ). Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder . International Journal of Neuropsychopharmacology , 9 (5) 603 – 605 .
   PubMed Web of Science ®Google Scholar
• Rogers , S. L. , Doody , R. S. , Mohs , R. C. and Friedhoff , L. T. 1998 . Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group . Archives of International Medicine , 158 ( 9 ) : 1021 – 1031 .
   PubMed Web of Science ®Google Scholar
• Rogers , S. L. , Farlow , M. R. , Doody , R. S. , Mohs , R. and Friedhoff , L. T. 1998 . A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group . Neurology , 50 ( 1 ) : 136 – 145 .
   PubMed Web of Science ®Google Scholar
• SAS ( 2004 ). [Computer software] . Cary, North Carolina : SAS Institute Inc .
   Google Scholar
• Saykin , A. J. , Gur , R. C. , Gur , R. E. , Mozley , P. D. , Mozley , L. H. Resnick , S. M. 1991 . Neuropsychological function in schizophrenia. Selective impairment in memory and learning . Archives of General Psychiatry , 48 ( 7 ) : 618 – 624 .
   PubMed Web of Science ®Google Scholar
• Saykin , A. J. , Shtasel , D. L. , Gur , R. E. , Kester , D. B. , Mozley , L. H. Stafiniak , P. 1994 . Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia . Archives of General Psychiatry , 51 ( 2 ) : 124 – 131 .
   PubMed Web of Science ®Google Scholar
• Sevy , S. , Rosenthal , M. H. , Alvir , J. , Meyer , S. , Visweswaraiah , H. Gunduz-Bruce , H. 2005 . Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications . Journal of Clinical Psychiatry , 66 ( 7 ) : 839 – 843 .
   PubMed Web of Science ®Google Scholar
• Sharma , T. , Reed , C. , Aasen , I. , & Kumari , V. ( 2006 ). Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation . Schizophrenia Research .
   Google Scholar
• Silver , H. , Shlomo , N. , Turner , T. and Gur , R. C. 2002 . Perception of happy and sad facial expressions in chronic schizophrenia: Evidence for two evaluative systems . Schizophrenia Research , 55 ( 1–2 ) : 171 – 177 .
   PubMed Web of Science ®Google Scholar
• Stryjer , R. , Strous , R. , Bar , F. , Shaked , G. , Shiloh , R. Rozencwaig , S. 2004 . Donepezil augmentation of clozapine monotherapy in schizophrenia patients: A double blind cross-over study . Human Psychopharmacology , 19 ( 5 ) : 343 – 346 .
   PubMed Web of Science ®Google Scholar
• Stryjer , R. , Strous , R. D. , Bar , F. , Werber , E. , Shaked , G. Buhiri , Y. 2003 . Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia . Clinical Neuropharmacology , 26 ( 1 ) : 12 – 17 .
   PubMed Web of Science ®Google Scholar
• Sumiyoshi , T. , Matsui , M. , Nohara , S. , Yamashita , I. , Kurachi , M. Sumiyoshi , C. 2001 . Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment . American Journal of Psychiatry , 158 ( 10 ) : 1722 – 1725 .
   PubMed Web of Science ®Google Scholar
• Szeszko , P. R. , Bilder , R. M. , Dunlop , J. A. , Walder , D. J. and Lieberman , J. A. 1999 . Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases . Biological Psychiatry , 45 ( 6 ) : 680 – 686 .
   PubMed Web of Science ®Google Scholar
• Tammenmaa , I. A. , Sailas , E. , McGrath , J. J. , Soares-Weiser , K. and Wahlbeck , K. 2004 . Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: A meta-analysis of randomized controlled trials . Progress in Neuropsychopharmacological and Biological Psychiatry , 28 ( 7 ) : 1099 – 1107 .
   PubMed Web of Science ®Google Scholar
• Tugal , O. , Yazici , K. M. , Anil Yagcioglu , A. E. and Gogus , A. 2004 . A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia . International Journal of Neuropsychopharmacology , 7 ( 2 ) : 117 – 123 .
   PubMed Web of Science ®Google Scholar
• Young , R. C. , Biggs , J. T. , Ziegler , V. E. and Meyer , D. A. 1978 . A rating scale for mania: Reliability, validity and sensitivity . British Journal of Psychiatry , 133 : 429 – 435 .
   PubMed Web of Science ®Google Scholar